Extramedullary hematopoiesis—the presence of hematopoietic activity in sites outside of the bone marrow—can occur in malignant and non-malignant hematologic diseases, and they may be a complication of primary myelofibrosis.
Extramedullary hematopoiesis (EMH)—the presence of hematopoietic activity in sites outside of the bone marrow, such as the liver or spleen—can occur in malignant and non-malignant hematologic diseases, and they may be a complication of primary myelofibrosis (PMF). EMH has been observed in the lymph nodes of some patients with PMF, and a recent case report describes a presentation of lymphadenopathy, secondary to EMH, that occurred as a patient’s first manifestation of PMF.
The report describes a 63-year-old patient who experienced generalized lymphadenopathy for 9 months, and had fever, night sweating, and weight loss. She had no history of hematologic illness. Computed tomography revealed lymphadenopathy in the mediastinal, abdominal, and pelvic lymph nodes, as well as enlargement of the liver and spleen. Additionally, sclerotic lesions throughout the patient’s skeletal system were observed.
Click to read more about myelofibrosis.
A lymph node biopsy showed no evidence of malignancy, though large abnormal cells were observed in the lymph nodes. A liver biopsy was negative for malignancy, but it showed inflammation and fibrosis with no evidence of EMH. After bone marrow examination and molecular studies, the patient’s final diagnosis was myeloproliferative neoplasm, consistent with PMF.
The patient was first treated with hydroxyurea at a dose of 500 mg/day, which resulted in only mild improvement, and dose escalation to 1 g/day did not produce good control of lymphadenopathy and splenomegaly. Next, the patient was given 10 mg of ruxolitinib twice daily, resulting in a dramatic response and a marked reduction of both spleen and lymph node size.
“EMH in a lymph node is a potential diagnostic pitfall in such [cases,] as it could be mistaken for metastatic cancer…Furthermore, presence of EMH can be problematic especially when evaluating lymph nodes during frozen section where morphology is frequently less than optimal,” write the authors. While they emphasize that EMH is not always a malignant process, a patient who has EMH should always be examined for underlying bone marrow disorders, as it may be the first manifestation of an underlying case of PMF.
Reference
Aljabry MS, Asiri S, Elsafi T, Elyamany G. Generalized lymphadenopathy secondary to isolated extramedullary hematopoiesis as an initial manifestation of primary myelofibrosis. Hematol Rep. 2018;10(2):7588. doi: 10.4081/hr.2018.7588.
NCCN Guidelines Update Adds Momelotinib Below Ruxolitinib for High-, Low-Risk Myelofibrosis
January 23rd 2024Momelotinib was given category 2A and 2B status for patients with high- and low-risk myelofibrosis (MF) and MF with anemia. However, ruxolitinib retains a higher category of recommendation as a treatment for patients with MF.
Read More
Oncology Onward: A Conversation With Dr Shereef Elnahal, Under Secretary for Health
April 20th 2023Shereef Elnahal, MD, MBA, under secretary for health at the Veterans Health Administration (VHA), sat for a conversation with our hosts Emeline Aviki, MD, MBA, Memorial Sloan Kettering Cancer Center, and Stephen Schleicher, MD, MBA, Tennessee Oncology, that covered the cancer footprint of the VHA.
Listen
Interventions Needed to Increase DMT Uptake in Sickle Cell Disease
December 26th 2023A recent study found that uptake of disease-modifying therapies (DMTs) has been low among patients with sickle cell disease, suggesting that more interventions that consider individual patient characteristics are needed to improve adoption.
Read More
Exploring Payer Coverage Decisions Following FDA Novel Drug Approvals
May 3rd 2022On this episode of Managed Care Cast, Ari D. Panzer, BS, lead author and researcher, then at Tufts Medical Center—now at Duke University—discusses the findings from his team’s investigation into coverage decisions by health plan insurers of the 66 drugs approved by the FDA in 2018.
Listen
Exagamglogene Autotemcel Meets End Points in Severe Sickle Cell Disease, β-Thalassemia
December 7th 2023Two posters set to be presented at the 65th American Society of Hematology Annual Meeting & Exposition met their primary and secondary end points regarding exagamglogene autotemcel therapy for sickle cell disease and β-thalassemia.
Read More